{"url_path":"/sec/kphmw/8-k/2026-05-08/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 Results of Operations and Financial Conditions.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-08","source_url":"https://www.sec.gov/Archives/edgar/data/1372514/0001372514-26-000048-index.html","accession_number":"0001372514-26-000048","cik":"0001372514","ticker":"KPHMW","issuer_name":"KIORA PHARMACEUTICALS INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1372514/0001372514-26-000048-index.html","primary_entity_key":"0001372514","primary_entity_name":"KIORA PHARMACEUTICALS INC"},"word_count":117,"has_tables":true,"body_markdown":"Item 2.02.    Results of Operations and Financial Conditions.\n\nOn May 8, 2026, Kiora Pharmaceuticals, Inc. (the “Company”) issued a press release announcing financial results for the quarter ended March 31, 2026 and an update on clinical development progress. A copy of the release is attached as Exhibit 99.1.\n\nThe information furnished pursuant to this Item 2.02, including Exhibit 99.1, is not deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section. This information will not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that the registrant specifically incorporates them by reference."}